Using predictive monitoring to improve patient care with rapid response teams
Feasibility and Initial Clinical Impressions of Predictive Monitoring Integrated With the RACE Team
NA · Ottawa Hospital Research Institute · NCT05108376
This study is testing if a new monitoring tool can help hospital teams spot patients at risk of serious health issues sooner, so they can provide better care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ottawa Hospital Research Institute (other) |
| Locations | 1 site (Ottawa, Ontario) |
| Trial ID | NCT05108376 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and initial clinical impressions of integrating the Visensia Safety Index (VSI) with rapid response teams (RRTs) in hospitals. The VSI utilizes continuous vital sign monitoring and machine learning to predict patient deterioration, allowing for timely interventions. By analyzing routinely collected data, the study aims to enhance patient outcomes by identifying those at risk of instability earlier. Initial findings suggest that the VSI could reduce the duration and frequency of serious patient instability.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are at high risk for deterioration due to surgery or serious medical conditions.
Not a fit: Patients in higher-level monitoring units or those receiving comfort care may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to quicker interventions and improved outcomes for high-risk hospitalized patients.
How similar studies have performed: Initial studies of the VSI have shown promising results, indicating that similar approaches may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Adult patient (greater than or equal to 18 years of age) designated for the most aggressive levels of potential intervention (Category 1 status - Full Care and Category 2 status - Full Care except CPR) who belong to one of the following groups: * Patients who have undergone high risk elective surgery (Whipple procedures, high risk vascular surgery, high risk general surgery, among others) * Malignant haematology or oncology patients at high risk for deterioration * Patients with infection admitted from the Emergency Department (ED) to the ward * Other high-risk patients determined at the discretion of the clinical team Exclusion Criteria: * Patients admitted to a unit with higher level monitoring (Neurological Acute Assessment Unit, Acute Monitoring Area, Trauma Step-Down, Intensive Care Unit) * Patients with Category III (Full Care except Respiratory or Hemodynamic Life Support, or CPR) or IV status (Comfort Care)
Where this trial is running
Ottawa, Ontario
- The Ottawa Hospital — Ottawa, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Andrew JE Seely, MD, PhD, FRCSC — The Ottawa Hospital
- Study coordinator: Andrew JE Seely, MD, PhD, FRCSC
- Email: aseely@toh.ca
- Phone: 613-737-8899
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Deterioration, Clinical